SR

Active Director Director DIN 09133668
DIN 09133668 First appointment Apr 2021 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2021
Shareholding value •••• Premium profile

About Seema Rao

Data last updated:

Seema Rao is a Director at Synbiodic Pharmaceuticals Private Limited (since 2021). The company operates in Healthcare. Synbiodic Pharmaceuticals Private Limited reported revenue of ₹9 Lakh (FY 2025).

DIN 09133668
Primary Designation Director
Industry Healthcare
First Appointment 05 Apr 2021
Oldest Company Age 5 yrs
Largest company Synbiodic Pharmaceuticals Private Limited · ₹9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director05 Apr 20212021₹9 Lakh (FY 2025)Active

Board colleagues of Seema Rao

NameDINCompanyDesignation
Bashist Rao09133667Synbiodic Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Synbiodic Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Seema Rao

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Seema Rao

Seema Rao currently holds 1 directorship: Synbiodic Pharmaceuticals Private Limited (Director, since 05 Apr 2021, revenue ₹9 Lakh (FY 2025)).

Seema Rao was first appointed on 05 Apr 2021 as Director at Synbiodic Pharmaceuticals Private Limited.

The current boards of Seema Rao's companies include Bashist Rao (Synbiodic Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available